NYSE:BAX

Baxter Reports First-Quarter 2024 Results

Retrieved on: 
Thursday, May 2, 2024
Medical Supplies, Medical Devices, Health, Pharmaceutical, Optical, Biotechnology, Sale, FDA, Baxter, Pharmacist, Sodium chloride, Food, Growth, LVP, SYR, Novum, Baxter International, Nursing, Patient, EPS, CDT, BPS, GAAP, Food and Drug Administration, Vasopressin

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.
  • Regardless of the selected path, Baxter currently expects the separation of its Kidney Care business to take place in the second half of 2024.
  • For full-year 2024: Baxter now expects sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis.
  • A webcast of Baxter’s first-quarter 2024 conference call for investors can be accessed live from a link in the Investor Relations section of the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on May 2, 2024.

Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Cardiology, FDA, Baxter, USP, Sodium chloride, Injection, Blood pressure, Baxter International, Anesthesia, Patient, Regadenoson, Antimalarial medication, Infection, Hypotension, Catecholamine, Vasopressin, Vancomycin, Pharmaceutical industry

“We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”

Key Points: 
  • “We are proud to offer important new options for our customers and look forward to continuing to bring new innovations to the market.”
    Product launches within Baxter’s Pharmaceuticals portfolio in the U.S. include the following.
  • For all products, please see full Indications, Important Risk Information and links to full Prescribing Information below.
  • Baxter offers the first and only FDA-approved ready-to-use Norepinephrine in Dextrose, and now provides Norepinephrine in 4 mg/250 mL, 8 mg/250 mL and 16 mg/250 mL strengths.
  • Baxter now offers Vancomycin in 500 mg/100 mL, 750 mg/150 mL, 1 g/200 mL, 1.25 g/250 mL and 1.5 g/300 mL strengths.

Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors

Retrieved on: 
Wednesday, April 10, 2024
Surgery, Medical Devices, Medical Supplies, Hospitals, Health Technology, Practice Management, Biotechnology, Health, General Health, Baxter International, Central Time, Webcast, Medtech

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 2024 at 7:30 a.m. Central Time.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its first-quarter 2024 financial results on Thursday, May 2, 2024 at 7:30 a.m. Central Time.
  • To participate in this conference call please follow this link https://registrations.events/direct/Q4I215737 to pre-register for the call and receive the call information.
  • This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com .
  • The conference call will be recorded by Baxter and is copyrighted material.

Investigation Alert Acadia Healthcare, Virtu Financial, Baxter International, and Hawaiian Electric: Johnson Fistel, LLP Encourages Investors to Submit Their Information Below

Retrieved on: 
Thursday, March 28, 2024
Virtu Financial, Baxter International, Hawaiian Electric Industries, Risk, SAN, LLP, Virtu, Complaint, HE, Wildfire, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) ("Acadia") against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) ("Acadia") against certain of its officers and directors.
  • If you have continuously owned Virtu Financial, Inc, shares since before March 1, 2019, submit your information below:
    Recently a class action lawsuit was filed against the company.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Baxter International, Inc. (NYSE: BAX).
  • Johnson Fistel, LLP is investigating potential claims on behalf of Hawaiian Electric Industries, Inc. against certain of its officers and directors.

Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Retrieved on: 
Monday, April 1, 2024
Technology, Medical Devices, Hospitals, FDA, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, SYR, Novum, LVP, EMR, Patient, State, Food and Drug Administration, CQI, Hospital, Pharmacist, Baxter International, Computer security, Safety, Nursing, Baxter, Medicine, Pump, Food, Medical device

Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software.
  • Offering the Novum IQ LVP in the U.S. demonstrates Baxter’s commitment to continued innovation in advancing infusion therapy.
  • “The Novum IQ platform represents a meaningful shift in how connected and intelligent infusion therapy can impact the way clinicians provide care.
  • IQ Enterprise Connectivity Suite, a scalable all-in-one server, integration engine and software application platform, designed to simplify infusion system connectivity for the Novum IQ Infusion Platform.

Baxter to Host Annual Meeting of Stockholders in Virtual Format

Retrieved on: 
Wednesday, March 27, 2024
Health Technology, Health, Medical Supplies, Online, Medtech, Central Time, Baxter International, Baxter, Annual general meeting, Holding company

Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter’s proxy statement for the 2024 Annual Meeting.
  • As always, whether or not a stockholder plans to attend the virtual 2024 Annual Meeting, all stockholders of record are encouraged to vote their shares prior to the 2024 Annual Meeting by one of the methods described in the proxy materials for the 2024 Annual Meeting.
  • A list of Baxter's stockholders of record will be available for examination by stockholders on the 2024 Annual Meeting website during the meeting.
  • Stockholders that have not voted their shares prior to the 2024 Annual Meeting will be able to vote their shares electronically at the 2024 Annual Meeting by clicking “Vote Here” on the meeting website.

Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation

Retrieved on: 
Wednesday, February 21, 2024
Baxter International, PMX, Sepsis, Intensive care unit, Amend, Investment, FDA, TSX, U.S. FDA, Risk, Baxter, Patient, Septic shock, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.

Key Points: 
  • TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.
  • Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”).
  • “Baxter’s continued commitment to Spectral as our exclusive supply and distribution partner being extended for a ten-year period upon U.S. FDA approval provides us with great confidence in our commercialization path,” said Chris Seto, CEO of Spectral Medical.
  • On February 15, 2024, Spectral announced that it had reached the 90-patient enrollment threshold and provided written notification to Baxter of this achievement.

Baxter to Present at Raymond James 45th Annual Institutional Investors Conference

Retrieved on: 
Thursday, February 29, 2024
Health Technology, Health, Medical Supplies, Medtech, Conference, Baxter International

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024.
  • Joel Grade, Baxter’s chief financial officer, is scheduled to present at 4:00 p.m. Eastern Time.
  • The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Friday, May 31, 2024.

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Retrieved on: 
Thursday, February 15, 2024
Baxter International, PMX, Sepsis, Intensive care unit, Spectral, FDA, TSX, Baxter, Patient, Septic shock, Acceleration, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.

Key Points: 
  • TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.
  • Under the terms of the Company’s Exclusive Distribution Agreement with Baxter International (“Baxter”) (NYSE:BAX), at Interim Enrollment, Baxter has the option to make a second milestone payment to Spectral to maintain its PMX exclusive distribution rights.
  • As such, Spectral has formally notified Baxter of reaching its Interim Enrollment target of 90 patients.
  • “Enrolling patient 90 represents a major milestone in many ways for Spectral as we continue to see acceleration across our Tigris trial sites and building confidence and momentum towards completing the trial,” said Chris Seto, CEO of Spectral Medical.

Baxter Declares Quarterly Dividend

Retrieved on: 
Monday, February 12, 2024
Health, Health Technology, Baxter International

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
  • The dividend is payable on April 1, 2024, to stockholders of record as of March 1, 2024.
  • The indicated annual dividend rate is $1.16 per share of common stock.